What are the key pathological features used to diagnose leukemia?
Key pathological features for diagnosing leukemia include the presence of an abnormal increase in white blood cells, blast cells in the bone marrow, atypical cell morphology, and specific chromosomal abnormalities or genetic mutations. Bone marrow biopsy and blood tests are commonly used diagnostic tools.
What are the common subtypes of leukemia and how are they differentiated in pathology reports?
The common subtypes of leukemia are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Chronic Myeloid Leukemia (CML). They are differentiated in pathology reports based on the cell type involved (lymphoid or myeloid), the maturity of the cells, and specific genetic markers.
How does leukemia pathology differ between acute and chronic forms?
Acute leukemia is characterized by the rapid proliferation of immature blood cells, known as blasts, which crowd out normal cells, leading to quick onset and progression of symptoms. Chronic leukemia progresses more slowly, involving the accumulation of more mature, yet dysfunctional, blood cells, resulting in more gradual symptom development.
How does the pathological examination contribute to determining the prognosis of leukemia?
Pathological examination in leukemia assesses factors like blast cell percentage, cytogenetic abnormalities, and immunophenotyping, which together help determine disease severity and subtype. This assessment guides prognosis by identifying characteristics linked to aggressive disease, treatment response, and potential outcomes, allowing for personalized therapy and close monitoring strategies.
What role does molecular pathology play in the diagnosis and classification of leukemia?
Molecular pathology plays a crucial role in leukemia diagnosis and classification by identifying genetic mutations and chromosomal abnormalities, aiding in precise diagnosis, determining prognosis, and guiding targeted therapy decisions. It allows for the detection of minimal residual disease and the monitoring of treatment response.